Nadunolimab is under clinical development by Cantargia and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Nadunolimab’s likelihood of approval (LoA) and phase transition for Head And Neck Cancer Squamous Cell Carcinoma took place on 30 May 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 30 May 2022 increased Nadunolimab’s Phase Transition Success Rate (PTSR) for Melanoma, and increased LoA and PTSR for Transitional Cell Cancer (Urothelial Cell Cancer).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Nadunolimab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Nadunolimab overview

Nadunolimab (CAN-04) is under development for the treatment solid tumours including urothelial cancer, liver cancer, esophageal cancer, head and neck cancer, metastatic non-small cell lung cancer, extrahepatic cholangiocarcinoma, gallbladder cancer, pancreatic ductal adenocarcinoma, triple negative breast cancer, colorectal cancer, bladder cancer, colon cancer, malignant melanoma, metastatic biliary tract cancer, metastatic pancreatic cancer, squamous non-small cell lung cancer and other solid tumors. It is administered by intravenous route. The drug candidate acts by targeting leukemic stem cells by binding to the IL1-RAP receptor. It was also under development for acute lymphocytic leukaemia, and chronic myelocytic leukaemia.

Cantargia overview

Cantargia, a subsidiary of Lund University Bioscience AB is a biotechnology company that develops antibody-based cancer treatments. The company’s product candidate CAN04 is used for the treatment of cancers including non-small cell lung cancer and pancreatic cancer. It utilizes cell surface receptors as a target to develop a novel antibody-based therapy for the treatment of chronic myeloid leukemia and other forms of leukemia. Cantargia provides therapies for the treatment of hematological malignancies that uses the expression of cell surface receptor on hematopoietic stem cells. The company also develops antibody therapeutics to eradicate leukemia disease-causing stem cells. Cantargia is headquartered in Lund, Sweden.

Quick View Nadunolimab LOA Data

Report Segments
  • Innovator
Drug Name
  • Nadunolimab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.